Ipsen : Onivyde approuvé en 1L contre le cancer du pancréas
>Approbation de la FDA en 1L (vs 2L jusqu’ici) - Ipsen a reçu hier la notification de la FDA approuvant Onivyde® en association avec l’oxaliplatine, le fluorouracile et la leucovorine (Nalirifox), comme traitement de première ligne (1L) chez les patients adultes atteints d’un adénocarcinome du pancréas métastatique. Depuis 2015, Onivyde® était approuvé (également en association avec le fluorouracile et la leucovorine) mais après progression de la maladie après un trai...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.